Treatment options for isoniazid-resistant TB: safety, effectiveness, and drug levels with a standard regimen
Official title: Treatment of isoniazid-resistant tuberculosis: closing evidence gaps on safety, effectiveness, and pharmacokinetics of the standard regimen
Funded at Socios En Salud Sucursal Peru · NIH-11421427 · Data updated 2026-11-12
This grant studies whether a standard TB treatment plan that includes levofloxacin is safe and effective for people with isoniazid-resistant TB in Peru.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Socios En Salud Sucursal Peru NIH-funded |
| Lab location | 1 site (Lima, Peru) |
| Project start | June 18, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $132,182 |
| NIH project number | 5R01AI183405-03 |
| Project ID | NIH-11421427 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years and older with isoniazid-resistant TB in clinical follow-up at participating centers in Peru.
✕Less likely to help
People without isoniazid-resistant TB or those not treated with the levofloxacin-containing regimen may not benefit.
What this research studies
Tuberculosis that no longer responds to isoniazid is a major challenge, especially in Peru where it is relatively common. The project looks at a commonly recommended three-drug-plus-levofloxacin regimen over six months to see how well it works and what safety issues may arise. Researchers will monitor patients for adverse effects and measure drug levels in the blood to understand how the drugs behave in the body. The work is grounded in real patients receiving standard care to fill gaps in high-quality evidence.
Why it matters
Potential benefit: If successful, this research could clarify a safer, more effective treatment option for people with isoniazid-resistant TB and reduce liver toxicity risks.
How similar studies have gone: Prior guidelines rely on low-quality evidence; this study aims to provide higher-quality data on safety and effectiveness.
Where this research is happening
-
Socios En Salud Sucursal Peru
Lima, Peru Active
Researchers
- Principal investigator: Arriaga, Maria — Socios En Salud Sucursal Peru
- Study coordinator: Arriaga, Maria
Related research
Other NIH-funded projects on the same topics.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
-
How lung cavities and granulomas affect TB inflammation and drug levels
This project looks at how damaged lung areas in people with pulmonary tuberculosis influence inflammation and whether antibiotics reach those spots.
-
Urine color test to monitor TB medicine levels in children and adults
This project uses a simple urine color measurement to check how well TB medicines, especially rifampin, reach the body in children and adults.
-
Finding better ways to diagnose tuberculosis in young children in Malawi.
This study is looking for better ways to find tuberculosis in young children under five in Malawi, especially those who are very malnourished, to help improve their treatment and care.
-
Evaluating a new treatment for antibiotic-resistant tuberculosis
This study is looking at a new treatment for antibiotic-resistant tuberculosis to see how well it works and how safe it is for patients, so we can find better options for people dealing with this tough infection.
-
Improving treatment for isoniazid-resistant tuberculosis
This project tests whether replacing isoniazid with levofloxacin and adjusting doses gives safer, more effective treatment for adults with isoniazid-resistant TB.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.